Effective utilization of erythropoietin with intravenous iron therapy

Journal of Clinical Pharmacy and Therapeutics

Volumn 23, Issue 1, 1998, Pages 73-78

  Bhandari, S ^a,b   Brownjohn, A ^a   Turney, J ^a  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FERROUS SULFATE; IRON; IRON DEXTRAN; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COST BENEFIT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; FEMALE; FERRITIN BLOOD LEVEL; HEMODIALYSIS PATIENT; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; IRON DEFICIENCY; MALE; ORAL DRUG ADMINISTRATION; SUBCUTANEOUS DRUG ADMINISTRATION; SUBSTITUTION THERAPY;

ADULT; AGED; AGED, 80 AND OVER; ERYTHROPOIETIN; FEMALE; FERRITINS; FERROUS COMPOUNDS; HEMATINICS; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAVENOUS; IRON, DIETARY; IRON-DEXTRAN COMPLEX; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RENAL DIALYSIS;

EID: 0031876404     PISSN: 02694727     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2710.1998.00147.x     Document Type: Article

References (23)

1. Van Wyck DB. (1991) Iron dextran in chronic renal failure. Seminars on Dialysis, 4(2), 112-114.
2. Longernecker RE, Goffinet JA, Hindler ED. (1974) Blood loss during maintenance haemodialysis. Transactions of the American Society of Artificial Internal Organs, 20, 135.
3. Eschbach JW, Cook JD, Scribner BA, Finch CA. (1977) Iron balance in haemodialysis patients. Annals of Internal Medicine, 87, 710-713.
4. Macdougall IC, Hutton D, Cavill I, Coles GA, Williams JD. (1989) Poor response to treatment of renal anaemia with EPO corrected by iron given intravenously. British Medical Journal, 299, 157-158.
5. Anastassiades EG, Howarth D, Howarth J, et al. (1993) Monitoring of iron requirements in renal patients on EPO. Nephrological Dial Transplant, 8, 846-853.
6. Van Wyck DB, Stivelman JC, Ruiz J, Kirlin LF, Katz MA, Ogden DA. (1989) Iron status in patients receiving erythropoietin for dialysis associated anaemia. Kidney International, 35, 712-716.
7. Milman N, Larsen L. (1976) Iron absorption in patients with chronic uraemia, undergoing regular haemodialysis. Acta Medica Scandinavica, 199, 113-119.
8. Fishbane S, Frei GL, Maesaka J. (1995) Reduction in recombinant human erythropoietin doses by the use of chronic intravenous iron supplementation. American Journal of Kidney Diseases, 26, 41-46.
9. Sunder-Plassmann G, Hörl WH. (1997) Erythropoietin and iron. Clinical Nephrology, 47, 141-157.
10. Lynn KL, Mitchell TR, Shepherd J. (1980) Serum ferritin concentration in patients receiving maintenance haemodialysis. Clinical Nephrology, 143, 124-127.
11. Nyvad O, Danielsen H, Madsen S. (1994) Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients. Lancet, 344, 1305-1306.
12. Lawson DH, Bodely K, King PC, Linton AL. (1971) Iron metabolism in patients with chronic renal failure on regular dialysis therapy. Clinical Science, 41, 345.
13. Gokal R, Millard PR, Weatherall DJ, Callener ST, Ledingham JGG, Oliver DO. (1979) Iron metabolism in haemodialysis patients. Quarterly Journal of Medicine, 191, 369-391.
14. Donnelly SM, Posen G, Ali MAM. (1991) Oral iron absorption in haemodialysis patients treated with EPO. Clinical Investigations in Medicine, 24, 271-276.
15. Sepandj F, Jindal K, West M, Hirsch D. (1996) Economic appraisal of maintenance parenteral iron administration in treatment of anaemia in chronic haemodialysis patients. Nephrology, Dialysis and Transplantation, 11, 319-322.
16. Sunder-Plassmann C, Hörl WH. (1994) Iron metabolism and iron substitution during EPO therapy. Clinical Investigation 72, 511-515.
17. Schaefer RM, Schaefer L. (1992) Management of iron substitution during human recombinant erythropoietin therapy in chronic renal failure patients. Erythropoiesis, 3, 71-75.
18. Fleming LW, Saleem AKN, Goodall HB, Stowart WK. (1984) Bone marrow iron and plasma ferritin in dialysed patients given intravenous iron-dextran. Clinical Laboratories and Haematology, 6, 23-32.
19. Ali M, Rigolosi R, Fayemi AO, Braun EV, Frascino J, Singer R. (1982) Failure of serum ferritin levels to predict bone-marrow iron content after intravenous iron-dextran therapy. Lancet, 1, 652-655.
20. Sunder-Plassmann G, Hörl W. (1995) Importance of iron supply for human recombinant erythropoietin therapy. Nephrology, Dialysis and Transplantion, 10, 2070-2076.
21. Weinberg ED. (1984) Iron withholds a defence against infection and neoplasia. Physiological Review, 64, 65-102.
22. Sussman HH. (1992) Iron in cancer. Pathobiology, 60, 2-9.
23. Ascherio A, Willet WC. (1994) Are body iron stores related to the risk of coronary heart disease? New England Journal of Medicine, 330, 1152-1154.